WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H523128
CAS#: 1977-11-3
Description: Perlapine is a potent and selective hM3Dq DREADD agonist (EC50 = 2.8 nM). This drug exhibits >10,000-fold selectivity for hM3Dq over hM3.
Hodoodo Cat#: H523128
Name: Perlapine
CAS#: 1977-11-3
Chemical Formula: C19H21N3
Exact Mass: 291.17
Molecular Weight: 291.398
Elemental Analysis: C, 78.32; H, 7.26; N, 14.42
Synonym: Perlapine
IUPAC/Chemical Name: 6-(4-Methyl-1-piperazinyl)-11H-dibenz[b,e]azepine
InChi Key: PWRPUAKXMQAFCJ-UHFFFAOYSA-N
InChi Code: InChI=1S/C19H21N3/c1-21-10-12-22(13-11-21)19-17-8-4-2-6-15(17)14-16-7-3-5-9-18(16)20-19/h2-9H,10-14H2,1H3
SMILES Code: CN1CCN(C2=NC3=CC=CC=C3CC4=CC=CC=C42)CC1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 291.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Meltzer HY, Fessler RG, Fang VS. Perlapine: relationship between stimulation of prolactin secretion and antipsychotic activity. Psychopharmacology (Berl). 1977 Oct 20;54(2):183-6. PubMed PMID: 412213.
2: Wilk S, Stanley M. Perlapine and dopamine metabolism: prediction of antipsychotic efficacy. Eur J Pharmacol. 1977 Jan 7;41(1):65-72. PubMed PMID: 12986.
3: Bürki HR, Ruch W, Asper H. Effects of clozapine, thioridazine, perlapine and haloperidol on the metabolism of the biogenic amines in the brain of the rat. Psychopharmacologia. 1975;41(1):27-33. PubMed PMID: 235767.
4: Allen SR, Oswald I. The effects of perlapine on sleep. Psychopharmacologia. 1973 Aug 22;32(1):1-9. PubMed PMID: 4359662.
5: Stille G, Sayers A, Lauener H, Eichenberger E. 6-(4-Methyl-1-piperazinyl)morphanthridine (Perlapine), a new tricyclic compound with sedative and sleep-promoting properties. A pharmacological study. Psychopharmacologia. 1973 Feb 20;28(4):325-37. PubMed PMID: 4695567.